Sapio Sciences’ Post

This new functionality unifies small-molecule, large-molecule, and multimodal discovery workflows, including entity registration, on a single platform.

🚀 Revolutionizing Drug Discovery with SPT LabTech Instruments! 🧪💡 The world of drug discovery is on the brink of a major transformation, and it's an exciting time to be at the forefront of this innovation. I'm thrilled to share how SPT LabTech's cutting-edge instruments are shaping the future of pharmaceutical research. SPT LabTech is setting the gold standard with its state-of-the-art instrumentation, enabling scientists and researchers to accelerate drug discovery and development in ways we could only dream of a few years ago. Here are some key highlights of what makes SPT LabTech instruments game-changers: High-Throughput Screening: SPT LabTech's instruments are designed to handle large volumes of compounds, significantly speeding up the screening process and allowing researchers to examine more potential drug candidates than ever before. ⚙️💼 Precision & Accuracy: When it comes to drug discovery, precision is everything. SPT LabTech's instruments offer unparalleled accuracy, ensuring that researchers can trust the results they obtain, a critical factor in decision-making. 🎯🔬 Automation & Robotics: The automation capabilities in SPT LabTech instruments streamline laboratory workflows, reducing human error and freeing up researchers to focus on data analysis and innovation. 🤖🧪 Versatility: From crystallography to liquid handling, SPT LabTech's instruments cover a wide range of applications in drug discovery, making them versatile tools for pharmaceutical research. 🌐🔍 Data Integration: SPT LabTech's commitment to user-friendly software and data integration solutions simplifies data management, analysis, and reporting, ultimately expediting the discovery process. 💻📈 As we strive to tackle some of the most pressing healthcare challenges, SPT LabTech's instruments play an integral role in our mission. Their impact is felt across the pharmaceutical industry, from large-scale research organizations to innovative biotech startups. 💪🌍 If you're as excited as I am about the future of drug discovery and the role of cutting-edge instrumentation in this journey, let's connect and discuss how we can collaborate to drive innovation and make a positive impact. Together, we can continue pushing the boundaries of what's possible in the world of healthcare. Learn more at https://lnkd.in/dmmV86J4. 🤝🔬 #DrugDiscovery #PharmaceuticalResearch #Innovation #LifeSciences #SPTLabTech #Biotechnology #ScienceMatters #LabInstruments

Finding the right CRO for your RNA-Seq experiments can be a challenging task. So how do you choose one?🔍 Clinical Research Organizations (CROs) come in a variety of sizes, from small companies to multi-billion dollar corporations, making it difficult for scientists to choose the perfect partner for their needs. In our latest blog posts, we walk you through the best-known RNA sequencing and data acquisition CROs and show you how you can take on the next challenge of analyzing and understanding your data🧬 Read the full article and learn how data generation and analysis can be seamlessly brought together into an end-to-end solution for efficient data analysis✨ --- CROs featured in this article: GENEWIZ, By Azenta Life Sciences Labcorp Eurofins Genomics Lexogen Psomagen LGC Genomics Division Sygnature Discovery #bioinformatics #computationalbiology #transcriptomics #rnaseq #rnaseqdata

Calling out to my awesome network to support our Cloud Lab, HTE, and Lab Automation Virtual Event! Its free and full of knowledge sharing! Whether you are a scientist, informatician, engineer, investor, or just someone who wants to constantly learn, we will have something for you! #investor #cloud #highthroughput #labautomation #scientificinformatics #researchanddevelopment #scienceandtechnology

💡Using global public research to enrich proprietary data can provide pharmaceutical companies with valuable new insights which can help inform strategic decisions. The re-use of this public data can be a very time and cost-efficient way to enable novel scientific exploration by fast tracking discovery and streamlining the process from R&D to clinical trial to market. Luckily, there are effective solutions to integrate various data sources in a cohesive and useful manner. Learn more in our latest blog.👇 #datascience #pharmaceuticals #research #drugdiscovery #publicdata

Right before we go into the weekend..., here's a short, clear blog that describes very well the needs we resolve for pharma every day. If you ever wanted to understand better the tech we develop, then I recommend you this blogpost. Happy reading. And, enjoy the weekend!

Our founder and CEO Jen Nwankwo, Ph.D. sat with Genetic Engineering & Biotechnology News to discuss our differentiated multimodal data strategy, which integrates computational data, wet lab proxy biological data, and wet lab ground truth biological data to overcome the low data regime problem that has historically limited the application of state-of-the-art foundational models in the pharmaceutical industry.    To advance small and large molecule drug discovery, we employ a multimodal AI platform powered by laboratory automation. Our platform’s name—Input, Transform, Output (ITO)—reflects our company’s comprehensive approach, spanning proprietary data generation, data orchestration, AI, and high throughput laboratory automation in iterative training and testing loops.    To gain access to our ITO platform, click here: https://lnkd.in/ek9dbk3T  Read the full GEN feature: https://lnkd.in/gynQxCjF   

Join us on December 7 at the Dutch Life Sciences Conference, for the latest insights in life sciences and medical technology. Among the sessions you are invited to attend the parallel morning session, hosted by Progress - Experts in Life Sciences: Artificial intelligence and the impact on product development and the product Life Cycle 2023 has been a year of record spending on artificial intelligence in the pharmaceutical industry. But while drugs, therapeutics and diagnostics of the future may be invented and operated by AI, it also presents challenges in areas such as data collection, regulation and validation. Questions like what are some of the underexplored applications for AI in pharma R&D? And what are the more common AI-related operational issues in R&D? Questions like these along with the regulatory landscape of AI and the validation of AI applications will be discussed during this session. The session is chaired by Christophe Mombers, consultant at Progress - Experts in Life Sciences. Speakers in this session include ARUNAVA GHOSH, Progress - Experts in Life Sciences and Quality and Regulatory Compliance Consultant, Joren van der Horst, Founder of Luo Automation and Stef van Grieken, Co-founder and CEO of Cradle. Read more about the sessions and speakers at Dutch Life Sciences Conference 2023 here: https://lnkd.in/gx8GhCJ Be sure to book your ticket soon, there is a limited number of tickets available. Register now: https://lnkd.in/gDRMcDA #dutchlifesciencesconference #progress #medicaldevice #AI #artificialintelligence #lifesciences #session #speakerprofile #datacollection #opportunity #regulation #validation

🔬💻 𝙁𝙪𝙨𝙞𝙤𝙣 𝙤𝙛 𝘽𝙞𝙤𝙨𝙩𝙖𝙩𝙞𝙨𝙩𝙞𝙘𝙨 𝙖𝙣𝙙 𝘽𝙞𝙤𝙞𝙣𝙛𝙤𝙧𝙢𝙖𝙩𝙞𝙘𝙨 𝙞𝙣 𝘽𝙞𝙤𝙥𝙧𝙤𝙘𝙚𝙨𝙨 𝘿𝙚𝙫𝙚𝙡𝙤𝙥𝙢𝙚𝙣𝙩 𝙖𝙣𝙙 𝘿𝙧𝙪𝙜 𝘿𝙞𝙨𝙘𝙤𝙫𝙚𝙧𝙮 💊📊 Biostatistics and bioinformatics have been pivotal in understanding genomic data and optimizing clinical trials. But let's broaden our perspective! The marriage of these disciplines with machine learning and modeling is revolutionizing bioprocess development and drug discovery. 〽 𝗕𝗶𝗼𝗽𝗿𝗼𝗰𝗲𝘀𝘀 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁: Gone are the days of relying solely on manual experimentation in bioprocessing. With the integration of biostatistics and bioinformatics alongside machine learning algorithms, we're unlocking efficiencies and insights like never before. From optimizing fermentation conditions to enhancing downstream processing, data-driven approaches are streamlining workflows and accelerating product development timelines. 🧬 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆: Traditional drug discovery pipelines can be resource-intensive and time-consuming. However, by harnessing the power of biostatistics and bioinformatics, we're reimagining how we identify promising drug candidates. From virtual screening to predictive modeling of compound interactions, these interdisciplinary approaches are enabling researchers to navigate vast datasets with precision, identifying novel targets and compounds with greater accuracy and efficiency. 🚀 𝗕𝗲𝘆𝗼𝗻𝗱 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀: While genomics and clinical trials remain crucial domains, the expansion of machine learning and modeling into bioprocess development and drug discovery heralds a new era of innovation. By leveraging advanced analytics and computational techniques, we're not only enhancing our understanding of biological systems but also transforming how we bring therapeutics from bench to bedside. 🔍 𝗟����𝗼𝗸𝗶𝗻𝗴 𝗔𝗵𝗲𝗮𝗱: As the intersection of biostatistics and bioinformatics continues to evolve, so will our ability to address complex challenges in bioprocessing and drug discovery. By fostering collaboration across disciplines and embracing emerging technologies, we're poised to unlock new frontiers in healthcare and biotechnology. 💡 𝗟𝗲𝘁'𝘀 𝗖𝗼𝗻𝗻𝗲𝗰𝘁: Are you leveraging the power of biostatistics, bioinformatics, and machine learning in your bioprocess development or drug discovery efforts? #Biostatistics #Bioinformatics #MachineLearning #Bioprocessing #DrugDiscovery #DataScience #Innovation #Healthcare #Biotechnology #Collaboration mb3-biostatistics.com

We participated in @AtomwiseInc #AIMS study published in Nature SciReports highlighting #AtomNet as a viable alternative to high-throughput screening! Read about the largest and most comprehensive virtual HTS campaign to date: https://lnkd.in/d3RsSAGd #drugdiscovery #AI #pharma #biotech